Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
Baxter
Citi
Covington
Boehringer Ingelheim

Generated: September 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207695

  Try a free trial


See Plans and Pricing

« Back to Dashboard

NDA 207695 describes EUCRISA, which is a drug marketed by Anacor Pharms Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the EUCRISA profile page.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the crisaborole profile page.
Summary for 207695
Tradename:EUCRISA
Applicant:Anacor Pharms Inc
Ingredient:crisaborole
Patents:4
Generic Entry Opportunity Date for 207695
Generic Entry Date for 207695*:
Constraining patent/regulatory exclusivity:
Dosage:
OINTMENT;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 207695
Suppliers and Packaging for NDA: 207695
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EUCRISA crisaborole OINTMENT;TOPICAL 207695 NDA Pfizer Laboratories Div Pfizer Inc 55724-211 55724-211-11 1 TUBE in 1 CARTON (55724-211-11) > 100 g in 1 TUBE
EUCRISA crisaborole OINTMENT;TOPICAL 207695 NDA Pfizer Laboratories Div Pfizer Inc 55724-211 55724-211-21 1 TUBE in 1 CARTON (55724-211-21) > 60 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:OINTMENT;TOPICALStrength2%
Approval Date:Dec 14, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 14, 2021
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:  Try a Free TrialPatent Expiration:Jun 11, 2026Product Flag?YSubstance Flag?YDelist Request?
Patent:  Try a Free TrialPatent Expiration:Jan 20, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
US Department of Justice
Cantor Fitzgerald
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.